Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Oral Presentations

Oral Session 10: Young Investigators / Clinical and Translational

Previous section
Oral Session 9: Thyroid Cancer Clinical
Table of contents
Next section
Oral Session 11: Young Investigators / Basic

ea0084op-10-47 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Putative protective role of anti-nuclear antibodies in graves’ orbitopathy

Lanzolla Giulia , Comi Simone , Puccinelli Lisa , Menconi Francesca , Marcocci Claudio , Marino' Michele

Objectives: A sporadic association between thyroid and non-organ-specific autoimmunity has been reported, which could be relevant for Graves’ orbitopathy (GO), an autoimmune disease affecting orbital connective tissue. We investigated whether there is an association between GO and anti-nuclear antibodies (ANAs).Methods: We performed a cross-sectional investigation in 265 consecutive patients with Graves’ disease (GD) who came to our observation...
1 shares

ea0084op-10-48 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Abstract Withdrawn...
0 shares

ea0084op-10-49 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

TSH-receptor antibodies among 1,024 early pregnant women in the north denmark region: cut-off, prevalence, and follow-up

Maria Uldall Torp Nanna , Henrik Bruun Niels , Astrup Christensen Peter , Handberg Aase , Andersen Stig , Linding Andersen Stine

Objectives: Measurement of TSH-receptor antibodies (TRAb) in hyperthyroid, pregnant women is an important tool when distinguishing between the autoimmune Graves’ disease and the physiological gestational hyperthyroidism. Evidence to support a cut-off for TRAb in early pregnancy is needed along with information on the frequency and follow-up of TRAb-positive as opposed to TRAb-negative hyperthyroidism.Methods: Within the North Denmark Region Pregnanc...
0 shares

ea0084op-10-50 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

Roque Joao , Silva Tiago , Leite Valeriano

Introduction and objectives: Poorly differentiated thyroid carcinoma (PDTC) is a rare but aggressive thyroid tumor. PDTC frequently presents in advanced stages and conventional treatments are usually less effective than in differentiated thyroid carcinoma (DTC). Lenvatinib is a multi-kinase inhibitor approved for the treatment of radioiodine-refractory DTC, with significant improvement in progression free survival. Despite the inclusion of a minority PDTC patients in SELECT tr...
0 shares

ea0084op-10-51 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Hypocalcemia is a frequent and life-threatening effect during lenvatinib treatment

Trevisan Matteo , Moneta Claudia , Colombo Carla , Giancola Noemi , Persani Luca , Fugazzola Laura , De Leo Simone

Objectives: Lenvatinib treatment is responsible for several adverse events (AEs). Hypocalcemia has been described in the registration study in 7% of patients, being of grade ≥3 in 2.7% of cases. No real-life studies are available, and the actual impact of this AE during Lenvatinib treatment is still unknown. Aim of our study is to evaluate the frequency of hypocalcemia in our series of patients treated with Lenvatinib and the possible predictors of this side effect.<...
0 shares

ea0084op-10-52 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Outcome of sporadic medullary thyroid cancer (MTC) patients with a biochemical persistent disease after initial treatment

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Torregrossa Liborio , Elisei Rossella , Matrone Antonio

Introduction: MTC is a rare neuroendocrine tumor arising from thyroid parafollicular cells. After initial treatment, patients should be divided according to their clinical status in cured, biochemical persistence (BIO) and structural persistence (STR) of the disease. Concerning BIO patients less is known about the structural disease appearance rate and the time elapsed between the first evaluation after surgery and the appearance of structural disease.Me...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more